Investor Relations
We are pleased to report that Accreditation certificate of foreign animal drug manufacturer for Friulchem S.p.A. was issued on 12 October 2018. This certificate is an important milestone for our company and represents a serious commitment to continuous improvement as we proceed along our path.
Today, the association Unione Industriali Pordenone has published an article on Friulchem S.p.A. In their section “Imprese in evidenza”, they talk about our company and our future projects. Read here.
In the next forthcoming CPhI China, you will be able to discover more on Evultis products and the new Joint Venture. The new collaboration in China allows Evultis to be up to date on the market situation, and propose the best solutions for its partners. Evultis 2018
Visit CPhI China Friulchem is glad to meet you at Kerry Hotel – Club Lounge meeting room 2 for presenting its news. Contact us at friulchem@friulchem.com
CPhI Japan is the opportunity to meet the country’s industry leaders.This event has been the central platform for international businesses for over ten years, where decision makers from Japan and overseas connect and do business. Friulchem will attend this important event. Meet us at stand IP-14.
Chinese New Year, also known as the Spring Festival in modern China, often called the Lunar New Year in Asia, is an important Chinese festival celebrated at the turn of the traditional lunisolar Chinese calendar.
Friulchem will attend to CPhI Japan 2018. CPhI Japan is Japan’s most comprehensive pharma event, which brings together more than 20,000 pharma industry professionals from 55+ countries. A wide range of exhibitors from all pharma areas active in Japan as well as free to attend seminars presented by governmental bodies and other important institutions is what …
The group Evultis SA – Friulchem S.p.A. started a new collaboration in China that allows it to be up to date on the market situation and to be able to satisfy customers requests promptly. This way the group will be faster in providing the information to the partners.
DCAT Value Chain Insights published a new article on Patent Ruling for Rifaximin. Mexican Institute of Industrial Property (IMPI), the patent and trademark administration body of Mexico, recently dismissed a patent-infringement and unfair competition case filed against Interquim, S.A. de C.V. Read more